cagrisema vs tirzepatide in Clinical Trials: What Patients Should Know The Real Story Behind CagriSema's

~60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development

doi:10.1002/hep.28431 Wegovy is a registered trademark of Novo Nordisk A/S

It allows Novo to defend its semaglutide franchise while broadening access to patients who prefer oral therapy

Food and Drug Administration (2024)

Each kidney has about a million of these filtration units called the glomeruli, which make up the nephrons

The FDA supports expanded access programs that can provide patients with serious or life-threatening conditions access to investigational treatments when no comparable or satisfying approved therapies are available, Hilliard said